Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 81 Scenario ∆ QALY ∆ soc- ietal cost (in mio. €) a ICER (€/ QALY) - Societal perspec- tive ∆ health- care cost (in mio. €) a ICER (€/ QALY) - Health- care payer perspec- tive Induced IS/com- plicated IS cases Induced IS: prevent- ed fatal cases Induced IS: pre- vented hospital- ized cases Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) w.r.t. productivity losses Caregiver work ab- sence as in 8 b 1139 (426- 2022) -16.8 (-20.5-- 13.6) cost-sav- ing (cs-cs) -11.1 (-14.2-- 8.4) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) w.r.t. assumed QALY losses (in baseline: 0.0011, 0.0022, 0.0034 and 0.0026 for mild, moderate, severe and nosocomical infections, respectively) QALY losses as in 8 c 1134 (421- 2017) -17.0 (-20.8-- 13.6) cost-sav- ing (cs-cs) -11.1 (-14.2-- 8.4) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) higher QALY losses 9 d 1146 (433- 2029) -17.0 (-20.8-- 13.6) cost-sav- ing (cs-cs) -11.1 (-14.2-- 8.4) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) w.r.t. assumed discount rate (3% for costs and effects in baseline) Discount rate: 0% effects & costs 2385 (792- 4363) -22.6 (-27.6-- 18.2) cost-sav- ing (cs-cs) -14.8 (-18.9-- 11.2) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) Discount rate: 2% effects & costs 1435 (528- 2560) -18.6 (-22.7-- 14.9) cost-sav- ing (cs-cs) -12.2 (-15.6-- 9.2) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) Discount rate: 4% effects & costs 916 (349- 1615) -15.5 (-19.0-- 12.5) cost-sav- ing (cs-cs) -10.1 (-13.0-- 7.6) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920) Dutch Discount rates (ef-fects (1.5%) & costs (4%)) 10 1620 (583- 2909) -15.5 (-19.0-- 12.5) cost-sav- ing (cs-cs) -10.1 (-13.0-- 7.6) cost-sav- ing (cs-cs) 4.61/0.22 1:21 (1:12- 1:33) 1:1707 (1:1494- 1:1920)